ライフサイエンスコーパス: albuterol

1 eatment with a bronchodilator (180 microg of albuterol).

2 with COPD, including those "unresponsive" to albuterol.

3 /ml) and they lost the Qaw responsiveness to albuterol.

4 S)-enantiomer after long-term use of racemic albuterol.

5 d) was initiated 3 h before and 0.25 h after albuterol.

6 ing to viscoelastic tissues before and after albuterol.

7 ol, and -3.45 +/- 0.92 mm Hg at 20 min after albuterol.

8 after administration of both salmeterol and albuterol.

9 n tolerance to the bronchodilator effects of albuterol.

10 as-needed ICS treatment coadministered with albuterol.

11 ing disorders before and after inhalation of albuterol.

12 ilar in both groups and did not change after albuterol.

13 scribed racemic albuterol is composed of (S)-albuterol.

14 oride and after reversal of provocation with albuterol.

15 the beta2AR-27 polymorphism and response to albuterol.

16 ht) was given orally with the second dose of albuterol.

17 EX, then challenged with media or 100 microM albuterol.

18 favorably to ephedrine, pseudoephedrine, or albuterol.

19 atients with COPD who received four puffs of albuterol.

20 and fenoterol and 100 times more potent than albuterol.

21 er nasal suctioning and a trial of nebulized albuterol.

22 not changed by TNF-alpha or by any isomer of albuterol.

23 se dependent manner, but not by (S) or (R,S)-albuterol.

24 uction scores were lower for sheep receiving albuterol.

25 0 minutes after inhalation of 180 micro g of albuterol.

26 e) and 200 microg metered-dose inhaler (MDI) albuterol.

27 ephedrine, 0.250 with dobutamine, 0.148 with albuterol, 0.194 with fenoterol, and 0.212 with epinephr

28 (S)-Albuterol (1 and 10 muM) induced Ca2+ oscillations, reac

29 Racemic albuterol 10(-5) M, salmeterol 10(-6) M, and isoproteren

30 luid clearance was increased by both racemic albuterol 10(-6) M (14.5 +/- 3.0%, p <.05) and R-enantio

31 (S)-Albuterol (10 muM) increased inositol-1,4,5-trisphosphat

32 ) and significantly less than that caused by albuterol (10.4 +/- 1.7).

33 y assigned to one of three treatment groups: albuterol (100 mug, two inhalations from a pressurized m

34 as also compared with unlabeled monodisperse albuterol (15-microg dose) and 200 microg metered-dose i

35 onsisted of baseline FEV1, pretreatment with albuterol 180 micrograms, postbronchodilator spirometry

36 lomethasone or placebo for each two puffs of albuterol (180 mug) needed for symptom relief.

37 gas for updraft nebulization of a mixture of albuterol 2.5 mg and ipratropium bromide 0.5 mg.

38 Additional aerosol treatments with albuterol 2.5 mg were given at 20, 40, and 120 mins afte

39 he children received a nebulized solution of albuterol (2.5 or 5 mg per dose, depending on body weigh

40 rine (100%) were 42% for fenoterol, 4.9% for albuterol, 2.5% for dobutamine, and 1.1% for ephedrine.

41 The IP(DVP) response to albuterol (400 microg by inhalation) was blunted in pati

42 volume pulse during intravenous infusion of albuterol (5 microg/min, DeltaRI(ALB)) and glyceryl trin

43 Albuterol (5.83 +/- 0.06 and 4.71 +/- 0.16) and fenotero

44 Medications included albuterol (81%), inhaled steroids (38%), cromolyn (35%),

45 acid (3), riluzole (6), hydroxyurea (7), and albuterol (9), none of which has demonstrated clinical e

46 ter inhalation of a standard beta 2-agonist, albuterol (A).

47 In addition, application of albuterol, a selective beta(2)-adrenoceptor agonist, sig

48 Albuterol acted as a sequential fast-acting channel bloc

49 termined the response to increasing doses of albuterol administered by a MDI and cylindrical spacer t

50 Delivery of albuterol administered by a MDI and spacer on filter pla

51 We hypothesized that albuterol administered via continuous nebulization would

52 Albuterol administration was repeated at operating frequ

53 Prior to albuterol administration, NFEV(1) was significantly high

54 sed airway resistance, which was reversed by albuterol aerosol treatment.

55 inhaled technetium-99m-labeled monodisperse albuterol aerosols (30-microg dose) of 1.5-, 3-, and 6-m

56 ssfully radiolabeled and imaged monodisperse albuterol aerosols within the human lungs.

57 ol (ISO) (beta(1) approximately beta(2)) and albuterol (ALB) (beta(2)>beta(1)).

58 ent asthma should not be treated with rescue albuterol alone and the most effective treatment to prev

59 reducing exacerbations than is use of rescue albuterol alone.

60 e and homogeneous changes in spirometry with albuterol, along with greater changes in these measures

61 not support use of nebulized magnesium with albuterol among children with refractory acute asthma.

62 to tiotropium include a positive response to albuterol and airway obstruction, factors that could hel

63 Test aerosols of albuterol and antibiotics were compared.

64 e observed beginning with the lowest dose of albuterol and continuing throughout the dose-response as

65 thma, the addition of ipratropium bromide to albuterol and corticosteroid therapy significantly decre

66 IP(DVP), whereas systemic administration of albuterol and GTN produced dose-dependent reductions in

67 nt with an oral corticosteroid and 3 inhaled albuterol and ipratropium treatments.

68 gonists with intermediate strengths, such as albuterol and salmeterol, stimulate GRK site phosphoryla

69 on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 2

70 re and after administration of 180 microg of albuterol, and a positive response was considered an inc

71 re and up to 4 h after inhalation of racemic albuterol, and determined the unchanged R/S ratio in uri

72 adenosine monophosphate (cAMP), salmeterol, albuterol, and isoproterenol in normal rat lung.

73 g SCF were premedicated with antihistamines, albuterol, and pseudoephedrine.

74 assess lower respiratory tract deposition of albuterol, and show that MDIs are more efficient for aer

75 e presence of the short-acting beta2-agonist albuterol, and the long-acting beta2-agonists formoterol

76 and ICAM-1 were not changed by any isomer of albuterol as measured by real time RT-PCR.

77 aily beclomethasone with beclomethasone plus albuterol as rescue (combined group); twice daily beclom

78 twice daily beclomethasone with placebo plus albuterol as rescue (daily beclomethasone group); twice

79 ); and twice daily placebo with placebo plus albuterol as rescue (placebo group).

80 twice daily placebo with beclomethasone plus albuterol as rescue (rescue beclomethasone group); and t

81 f Spiros and Ventolin (90- and 270-microgram albuterol base).

82 ured plasma levels of unchanged (R)- and (S)-albuterol before and up to 4 h after inhalation of racem

83 ects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as n

84 at Met772-AC9 is associated with an improved albuterol bronchodilator response in asthmatics was inve

85 ugh a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-

86 cohort of 203 527 patients who began taking albuterol but did not receive antipsychotic medication.

87 The effects of albuterol but not GTN on IP(DVP) were attenuated by N(G)

88 Although albuterol, but not the two placebo interventions, improv

89 5) decreases in Raw and tissue damping after albuterol, but tissue elastance decreased only in the Ty

90 response to regular versus as-needed use of albuterol by genotyping the 190 asthmatics who had parti

91 n minutes after administration of 180 microg albuterol by metered dose inhaler, mean Qaw increased by

92 m bromide with the second and third doses of albuterol; children in the control group received 2.5 ml

93 FR during treatment with regularly scheduled albuterol compared with placebo (14 L/min [95% CI 3 to 2

94 ergency department, nebulized magnesium with albuterol, compared with placebo with albuterol, did not

95 Filters were rinsed with water and albuterol concentrations determined by high performance

96 The filter was rinsed with water and albuterol concentrations were determined by high-perform

97 ontinuous nebulization group, or d) 40 mg of albuterol continuous nebulization group (n=5 animals per

98 e continuous nebulization group, c) 20 mg of albuterol continuous nebulization group, or d) 40 mg of

99 ferent from background rates observed in the albuterol control group.

100 After albuterol, control subjects showed no change in spiromet

101 bo-controlled trials have shown that inhaled albuterol decreases the duration of cough in adults with

102 used to determine significant differences in albuterol delivered or lost among the operating frequenc

103 These in vitro results suggest albuterol delivery by MDI in a pediatric model of HFOV i

104 Albuterol delivery from a MDI was increased when the ven

105 ined the effect of various He-O2 mixtures on albuterol delivery from metered-dose inhalers (MDIs) and

106 idity, and spontaneous respiratory effort on albuterol delivery in a model of the trachea and bronchi

107 Albuterol delivery showed a linear correlation with both

108 Albuterol delivery to the lower respiratory tract was de

109 Albuterol delivery to the lung simulator was <1% of the

110 the nebulizer was operated with O2, greater albuterol delivery was achieved when the ventilator circ

111 Albuterol delivery was significantly (p < or = .05) grea

112 ions and with a frequency of 10 breaths/min, albuterol delivery with CMV (VT, 800 ml; 30.3 +/- 3.4%),

113 anics and a 6.0-mm endotracheal tube improve albuterol delivery.

114 greater bronchodilation than 200 microg MDI albuterol (deltaFEV1 [ml]: 6 microm [551], 3 microm [457

115 likely due to the low-density gas improving albuterol deposition in the distal airways.

116 m with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitaliz

117 We conclude that 180 micrograms albuterol does not prevent excessive bronchoconstriction

118 demonstrates that, in emergency situations, albuterol does not relieve acute airway obstruction in a

119 In this tissue, albuterol does not stimulate exocytosis either in vivo o

120 The percentage albuterol dose lost in the circuit's expiratory limb and

121 statistically significant differences in the albuterol dose response following salmeterol or placebo.

122 Albuterol, due to its bronchodilatory and anti-inflammat

123 gned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or

124 Albuterol enhanced cardiac output reserve and right vent

125 In the remainder, albuterol, even in high doses, has little effect for day

126 d in the circuit's expiratory limb collected albuterol exiting the endotracheal tube and any albutero

127 ling efficiency, with ephedrine, dobutamine, albuterol, fenoterol, and epinephrine giving 0, 7, 17, 4

128 ditional inhaled short-acting beta2-agonists albuterol, fenoterol, and terbutaline provide rapid as-n

129 corticosteroids, post 180 microg aerosolized albuterol, FEV(1) was 74 +/- 23% predicted and FEV(1)/FV

130 erformed before and at 5-min intervals after albuterol for 80 min.

131 (S)-albuterol (the inactive isomer) or (R,S)-albuterol for 90 minutes before adding 2 ng/ml TNF-alpha

132 budesonide-formoterol group than in both the albuterol group (9 vs. 23; relative risk, 0.40; 95% CI,

133 -formoterol group was lower than that in the albuterol group (absolute rate, 0.195 vs. 0.400; relativ

134 dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 mug, one inhalation th

135 Compared with saline and control groups, the albuterol groups had lower pause and peak inspiratory pr

136 efficiency, i.e. epinephrine >/= fenoterol > albuterol > dobutamine > ephedrine.

137 terol = fenoterol > terbutaline = zinterol = albuterol > salmeterol > dobutamine > or = ephedrine.

138 d on the basis of bronchodilator response to albuterol (> 12% and > 200-ml improvement) and were rand

139 tudy Arg Arg patients who had regularly used albuterol had a morning peak expiratory flow 30.5 +/- 12

140 Racemic albuterol has been one of the most widely used beta2-adr

141 Inhaled albuterol, however, resulted in significant improvement

142 Albuterol improved the primary end point of exercise pul

143 day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of h

144 Continuous nebulization of albuterol improves pulmonary function via improved airwa

145 Albuterol improves pulmonary vascular reserve in patient

146 w (Qaw) and FEV (1) before and after inhaled albuterol in 19 glucocorticosteroid (GS)-naive patients

147 xpression was significantly inhibited by (R)-albuterol in a dose dependent manner, but not by (S) or

148 ncrease in Qaw and its hyporesponsiveness to albuterol in asthmatic subjects may be consequences of a

149 iability in response to therapeutic doses of albuterol in children.

150 tes to individual differences in response to albuterol in Latinos, notably in SLC genes that include

151 no decline in peak flow with regular use of albuterol in patients who were homozygous for glycine at

152 Improvements in FEV(1) after albuterol in patients with COPD are due to reduction of

153 Currently we have completed a pilot study of albuterol in patients with late-onset Pompe disease alre

154 thma severity and bronchodilator response to albuterol in Puerto Ricans and Mexicans with asthma.

155 05)-indicating preferential retention of (S)-albuterol in the lung.

156 Both (S)-and (R,S)-albuterol increased [Ca2+]i at concentrations of >10 pM

157 Albuterol increased Qaw by 27 +/- 3% in the control subj

158 ) was significantly (p < 0.01) reduced after albuterol inhalation (60.6 +/- 22.2 cm H(2)O/L/s) but pr

159 rolled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo.

160 We evaluated the response to albuterol inhalation in 10 healthy subjects, 9 subjects

161 However, post-albuterol inhalation, FEV(1) increased more than NFEV(1)

162 V1, 54 to 91% of predicted) before and after albuterol inhalation.

163 halation, and it is significantly reduced by albuterol inhalation.

164 vention did not differ significantly for the albuterol inhaler (50% improvement), placebo inhaler (45

165 were also given liquid dextromethorphan and albuterol inhaler with a spacer.

166 ents with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture,

167 ost patients (81%) reported benefit from the albuterol inhaler.

168 plications because 50% of prescribed racemic albuterol is composed of (S)-albuterol.

169 n dyspnea in patients with COPD with inhaled albuterol is in part due to increased diaphragmatic cont

170 treatment of ASM cultures with beta-agonists albuterol, isoproterenol, or salmeterol (100 nM to 10 mu

171 Serum albuterol levels (+/- SEM) quantitated by high-performan

172 Albuterol lost in the expiratory limb ranged from 3.28%

173 uterol exiting the endotracheal tube and any albuterol lost, respectively.

174 Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/A

175 The results also suggest that (S)-albuterol may cross-react with muscarinic receptors.

176 a Ca2+ agonist in airway smooth muscle, (S)-albuterol may have profound clinical implications becaus

177 to week 48 in mean daily number of puffs of albuterol, mean total asthma symptom score, and mean ove

178 In vitro, DEX treatment induced albuterol-mediated glandular exocytosis (p < 0.04), and

179 ial scrapings (p < 0.04), but did not induce albuterol-mediated glandular secretion.

180 ed corticosteroids as rescue medication with albuterol might be an effective step-down strategy for c

181 d at baseline and 10 min after inhalation of albuterol (n = 28) or placebo (n = 13) using a metered-d

182 bjects received saline or BDP for 3 d before albuterol nasal provocation.

183 had a significantly higher heart rate after albuterol nebulization compared with the control group.

184 We studied the spirometric effects of albuterol nebulized with heliox during emergency room vi

185 lude that during acute asthma exacerbations, albuterol nebulized with heliox leads to a more signific

186 rty-five patients were randomized to receive albuterol nebulized with oxygen (control) versus heliox

187 improvement in spirometry when compared with albuterol nebulized with oxygen.

188 ts had reversibility in FEV1 after nebulized albuterol of 15% or more and a mean postbronchodilator F

189 = 0.012) than Arg/Arg patients who had used albuterol on an as needed basis.

190 lbuterol regularly but not in those who used albuterol on an as-needed basis.

191 onsiveness, we determined the effects of (S)-albuterol on intracellular Ca2+ concentration ([Ca2+]i)

192 The effects of albuterol on IP(DVP) are mediated in part through the ni

193 L IMPLICATION: The suppressive effect of (R)-albuterol on neural ICAM-1 expression may be an addition

194 trolled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjec

195 atients randomly received inhaled placebo or albuterol on the first test day and the alternative medi

196 ranolol blocked the inhibitory effect of (R)-albuterol on TNF-alpha-induced ICAM-1 expression.

197 isomers (enantiomers) of beta(2)AR agonists, albuterol or formoterol.

198 Both groups received albuterol or levalbuterol prior to each study drug dose.

199 Eleven patients with COPD inhaled albuterol or placebo in a double-blind randomized manner

200 Regularly scheduled treatment with albuterol or placebo was given in a masked, cross-over d

201 re then randomized 1:1 to inhaled, nebulized albuterol or placebo.

202 r on vasodilator responses to acetylcholine, albuterol, or levcromakalim.

203 resistance occurred after administration of albuterol (p < 0.001).

204 n the group that received only four puffs of albuterol (p < 0.003).

205 re maintained for 6 h after the last dose of albuterol (p < 0.05).

206 to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tio

207 Albuterol produced a decrease in dyspnea (5 +/- 2 to 4 +

208 Compared with placebo, albuterol produced an increase in inspiratory capacity (

209 The (R)-enantiomer of racemic albuterol produces bronchodilation, whereas the (S)-enan

210 proved FEV(1) in these patients with asthma, albuterol provided no incremental benefit with respect t

211 sitive, and in these patients 5 to 7.5 mg of albuterol provides optimal treatment.

212 oint [CI, 0.15 to 0.43]), reduced mean daily albuterol puffs (-0.27 puff/d [CI, -0.49 to -0.04 puff/d

213 Albuterol recovery at 20 minutes after histamine challen

214 so declined in the Arg/Arg patients who used albuterol regularly but not in those who used albuterol

215 or arginine at B(2)-AR-16 (Arg/Arg) who used albuterol regularly.

216 In conclusion, albuterol relieves dyspnea and enhances respiratory musc

217 To determine the dose of albuterol required to terminate acute episodes of asthma

218 and 86.8%, respectively; P=0.50), use of an albuterol rescue inhaler (2.8 and 3.0 inhalations per we

219 Asthma patients who had not used an albuterol rescue inhaler in the past week were compared

220 scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared

221 inhaled corticosteroids were taken with each albuterol rescue use.

222 .3 times (1.3-4.2) more likely to respond to albuterol, respectively.

223 d clinical features, airflow limitation, and albuterol responsiveness in adults acutely ill with asth

224 nsistent with this AC9 polymorphism altering albuterol responsiveness in the context of concomitant i

225 r (beta(2)AR) may modify asthma severity and albuterol responsiveness.

226 ong the 39 patients who completed the study, albuterol resulted in a 20% increase in FEV(1), as compa

227 The disposition of albuterol's enantiomers with a MDI and holding chamber w

228 Albuterol (salbutamol) and glyceryl trinitrate (GTN) wer

229 ich all patients returned to using as-needed albuterol, so that by the end of the study Arg Arg patie

230 ressing Met772 had a significantly increased albuterol-stimulated adenylyl cyclase response (approxim

231 wer after treatment with the partial agonist albuterol, suggesting a correlation between the efficien

232 ator to produce (99m)Tc-labeled monodisperse albuterol sulfate aerosols of 1.5-, 3-, and 6- micro m m

233 Four formulations of albuterol sulfate and budesonide in sieved and milled la

234 examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlist

235 , evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life.

236 l treatment solutions were premedicated with albuterol sulfate.

237 at Puerto Ricans with asthma respond less to albuterol than do Mexicans with asthma.

238 had lower morning PEFR during treatment with albuterol than during the placebo period, when albuterol

239 Cells were incubated with either (R)-albuterol (the active isomer), (S)-albuterol (the inacti

240 ither (R)-albuterol (the active isomer), (S)-albuterol (the inactive isomer) or (R,S)-albuterol for 9

241 ral or intravenous administration of racemic albuterol, the (R)- enantiomer is metabolized several ti

242 itude but was more prolonged than that after albuterol, the greatest mean change being -2.74 +/- 0.89

243 After nebulized albuterol, the mean TGV decreased to 96.4 +/- 1.3% predi

244 fficacy in an open label study of adjunctive albuterol therapy in patients with late-onset Pompe dise

245 ice with Pompe disease following addition of albuterol therapy.

246 We hypothesized that targeting albuterol to regional airways by altering aerosol partic

247 Spiros actuation delivers 1.12 times as much albuterol to the airways as one Ventolin actuation (90%

248 in inhalers deliver comparable quantities of albuterol to the airways.

249 In terms of delivery of albuterol to the lungs, we compared an alternative deliv

250 Six of 28 albuterol-treated infants demonstrated increases in FEF(

251 Following albuterol Treatment 1, the median change in forced expir

252 ll subjects responded promptly to additional albuterol treatment, and no subject developed refractory

253 to 2.82 +/- 1.59, p < 0.001) after the first albuterol treatment.

254 .03]; P = .50); or mean number of additional albuterol treatments (magnesium: 1.49, placebo: 1.59; ri

255 Patients received nebulized albuterol treatments every 20 min with a maximum of thre

256 Three consecutive albuterol treatments were given to each group.

257 Participants were randomized to 3 nebulized albuterol treatments with either magnesium sulfate (n =

258 t 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes.

259 ores (-1.0 +/- 0.1 vs. -0.6 +/- 0.1), rescue albuterol use (-3.3 +/- 0.2 vs. -1.9 +/- 0.2 puffs/d), a

260 with moderate-to-severe asthma with frequent albuterol use and nighttime awakenings at least once wee

261 s the characterization of effects of regular albuterol use in patients with genetic variations in the

262 During the study, as-needed albuterol use was discontinued and ipratropium bromide w

263 During the run-in period, when albuterol use was kept to a minimum, patients with the A

264 buterol than during the placebo period, when albuterol use was limited (-10 L/min [-19 to -2]; p=0.02

265 ome spirometry, histamine challenge, inhaled albuterol use, and asthma symptom scores.

266 re function had more asthma symptoms, rescue albuterol use, and FEV(1) reversal (P < 0.001, 0.03, and

267 FEV1, peak expiratory flow, symptoms, rescue albuterol use, and quality of life scores, also did not

268 duced asthma symptom scores and supplemental albuterol use, and significantly increased the percentag

269 ength of indoor, PM-related asthma symptoms, albuterol use, and systemic inflammation.

270 mptoms and albuterol use, night symptoms and albuterol use, controller treatment, lung function measu

271 I scores include 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, control

272 c receptor affects the long-term response to albuterol use.

273 ning the effects of regular versus as needed albuterol use.

274 de-formoterol used as needed was superior to albuterol used as needed for the prevention of asthma ex

275 duled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chro

276 responsiveness to the inhaled beta-agonist, albuterol, using changes in maximal expiratory flows.

277 .M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5 and 2.6% with placebo (p = 0.0

278 ificantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M.

279 was significantly greater (p < 0.05) in the albuterol versus placebo group for FEV(0.5) (2.2% versus

280 The R/S ratio in urine at 0.5 h after albuterol was > 1, reflecting the higher plasma level of

281 ease in airway resistance with four puffs of albuterol was comparable to that observed with cumulativ

282 Albuterol was equally efficacious in both populations an

283 In 34% of participants, albuterol was ineffectual.

284 sus baseline), and the Qaw responsiveness to albuterol was restored ( +21 +/- 2%; p < 0.05) in the as

285 teroid) and a negative control drug (inhaled albuterol) was also assessed.

286 1 after cumulative doubling doses of inhaled albuterol were assessed after a 2-wk beta-agonist washou

287 e validation data showed that technetium and albuterol were coassociated on each impactor stage for a

288 Formoterol and albuterol were equally efficacious.

289 Four, eight, and 16 puffs of albuterol were given at 15-min intervals.

290 +/- SE) FEV(1) and FEV(1) responsiveness to albuterol were not affected by FP.

291 In contrast, bronchodilator responses to albuterol were similar in eosinophilic and noneosinophil

292 centage change in FEV(1) after 180 microg of albuterol, were adjusted to account for sex, age, height

293 The EPR was blocked by cromoglycate and albuterol, whereas the LPR was abolished by cromoglycate

294 sponse is in a stark contrast to that of (R)-albuterol, which decreased [Ca2+]i.

295 In summary, administration of albuterol with a MDI achieved a profile of serum levels

296 rdingly, 10 healthy subjects inhaled racemic albuterol with a MDI alone and with a MDI and holding ch

297 nantiomer disposition after inhaling racemic albuterol with a metered-dose inhaler (MDI) is not known

298 sters were used to administer 2000 microg of albuterol with a spacer.

299 ffects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in

300 zed that the inhaled beta-adrenergic agonist albuterol would improve pulmonary vasodilation during ex